Injection laryngoplasty outcomes in vocal fold paralysis using calcium hydroxylapatite.
This study aims to evaluate our injection laryngoplasty experience in patients with unilateral vocal fold paralysis. Sixty-eight patients (32 males, 36 females; mean age 59.5 years; range 27 to 86 years) who were diagnosed with unilateral vocal fold paralysis at our clinic and who underwent injection laryngoplasty using calcium hydroxylapatite between January 2005 and June 2012 were included in this study. Mean follow-up period was 36 weeks (range 0-340.4 weeks). Data of 29 patients with post-injection Voice Handicap Index (VHI) scores were retrospectively analyzed. Of these patients, 16 (55%) were female, and the mean patient age was 60 (range 27 to 86 years). Seventeen patients underwent suspension laryngoscopy in the operating room, 12 patients underwent in-office percutaneous injection. Post-injection mean VHI score was 36.7 (range 4 to 87). Percutaneous injection laryngoplasty was performed to half of the 20 patients with pre- and post-injection VHI data. Mean VHI scores of these 20 patients improved by 27.9 points. Mean VHI score improved by 35.1 points in the percutaneous group, and by 20.7 points in the suspension group (p=0.29). Post-injection VHI score of one patient with lung cancer decreased, as his general health deteriorated. This study supports injection laryngoplasty in vocal fold paralysis. Calcium hydroxylapatite is a safe and effective treatment method in both percutaneous and operating room procedures.